What should be done at the time of menopause?
- PMID: 7709937
- DOI: 10.1016/s0002-9343(05)80048-8
What should be done at the time of menopause?
Abstract
Peak bone mass and aggregate bone loss each contribute to low bone mass found later in life, and obviously the contribution of bone loss will increase as people age. Menopause is the time where bone loss begins to accelerate from the existing peak bone mass. It thus seems obvious that, in order to stratify the female population into groups at various risk, bone mass and rate of loss are the parameters to determine. Which site to measure for the most effective risk assessment has not been determined. All sites seem to give a relatively similar assessment of risk for all subsequent fractures. If the measurement is > 1 standard deviation (SD) above the mean for young normals, no further measurement would be needed and no intervention undertaken. If the measurement is < 1 SD below the mean for young normals, intervention would be recommended (provided no contraindications were present). For those within +/- 1 SD, the rate of loss should be determined. Some individuals lose bone at a more rapid rate than others, and this rapid rate may persist in some of these individuals over a period of years. Studies have shown that women that were classified to be fast losers at menopause have lost approximately 50% more bone mass, at the wrist, spine, and hip within 12 years after menopause than those diagnosed as normal bone losers. The rate of bone loss in postmenopausal women may be indirectly assessed by use of a number of biochemical markers. Fast losers have elevated concentrations of these markers compared with slow bone losers. The risk of developing osteoporosis later in life is thereby determined by combining the values for the present measured bone mass and the magnitude of the estimated future bone loss.
Similar articles
-
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study.Bone. 1996 Jul;19(1):9-12. doi: 10.1016/8756-3282(96)00102-0. Bone. 1996. PMID: 8830981
-
The role of bone loss.Am J Med. 1995 Feb 27;98(2A):29S-32S. doi: 10.1016/s0002-9343(05)80042-7. Am J Med. 1995. PMID: 7709930 Review.
-
Bisphosphonates for prevention of postmenopausal osteoporosis.Dan Med Bull. 2002 Feb;49(1):1-18. Dan Med Bull. 2002. PMID: 11894721 Review.
-
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.BMJ. 1991 Oct 19;303(6808):961-4. doi: 10.1136/bmj.303.6808.961. BMJ. 1991. PMID: 1954420 Free PMC article.
-
Fast and slow bone losers. Relevance to the management of osteoporosis.Drugs Aging. 1998;12 Suppl 1:1-7. doi: 10.2165/00002512-199812001-00001. Drugs Aging. 1998. PMID: 9673860 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources